T Cell Responses to Varicella Zoster Virus After Vaccination and Viral Escape
With increasing age, immune responses to vaccination begin to decline. A decrease in vaccination success rates is already evident in the 6th and 7th decade of life. With the changing demographics of the US population, this decline in immune function is a major health concern. The study of the immune responses to the naturally-acquired chicken pox virus and to the shingles vaccine will provide an important opportunity to learn more about the aging immune system and may lead to an improvement in vaccination strategies and identification of ways to improve vaccine responses in older individuals
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- biological : Zostavax?
Phase: Phase 4
Ages Eligible For Study:
- Otherwise healthy adult, 40-49 years of age (Cross-Sectional study)or 50 years of age and older (Vaccination study). If a volunteer cannot participate in the Vaccination study after screening, may be considered for Cross-Sectional study. - History of prior chicken pox infection or living within the continental U.S. for past 30 years - Willing to complete the informed consent process - Availability for follow-up for the planned duration of the study (Cross-Sectional study: 1 visit; Vaccination study: 5 visits within 4-5 weeks) - Acceptable medical history and vital signs
School of Medicine
300 Pasteur Drive
Stanford, CA 94305